Global Supplier Strategy for Market Penetration & Partnership Options (Niche Suppliers vs. National Leaders) in the Massachusetts Cardiology & Vascular Surgery Tools and Devices Market for Cardiac Operating Rooms and Angioplasty Suites
Curator: Aviva Lev-Ari, PhD, RN
The ecosystem of Cardiac and Vascular Surgery for Repair or Replacement by Implantation of a new blood vessel or medical device covers the following procedure-related devices and tools now in use:
- Arterial catheterization kit
- Embolectomy catheters
- Occlusion catheter
- Coronary stents
- Neurovascular stents
- Carotid stents
- External and internal carotid shunts
- Peripheral stents
- Biliary stents
- Micro vascular clips
- Stainless steel tunneler vascular graft
- Cardiopulmonary bypass vascular catheter
- Coronary stent graft system
- Catheter tip occluder
- Synthetic/biological composite vascular graft
- Valvulotome tools
- Aortic Valve
- Mitral Valve
- Angioplasty Guided Wires
No Aorta valve suppliers in MA. The National Leader supplier Edwards Lifesciences and its SAPIEN product for Transcatheter Aortic-Valve Implantation (TAVI) and Replacement (TAVR) is covered in Executive Compensation and Comparator Group Definition in the Cardiac and Vascular Medical Devices Sector: A Bright Future for Edwards Lifesciences Corporation in the Transcatheter Heart Valve Replacement Market 6/20/2012
Medical Devices Market in Massachusetts: Product Concentration Ratios (1 to 10) by Product and Partnership Target Advantage – Niche Suppliers vs. National Leader in the Cardiology & Vascular Surgery Tools and Devices in use in Cardiac Operating Rooms and in Angioplasty Suites
|
Industry Concentration Ratios per Product Line in the Cardiac and Vascular Medical Devices Segments |
|||||||||
|
A |
B |
C |
D |
E |
F |
G |
H |
I |
J |
|
US comparison |
MA comparison |
||||||||
| Cardiology & Vascular Surgery Tools and Devices in use |
Global Suppliers |
US Suppliers |
Market share |
Global ratio |
Index |
MA Suppliers |
Market share |
Global ratio |
Index |
| Arterial catheterization kit |
4 |
6 |
0.09 |
0.40 |
5.6 |
2 |
0.14 |
0.67 |
3.6 |
| Embolectomy catheters |
11 |
28 |
0.03 |
0.28 |
1.9 |
3 |
0.07 |
0.79 |
2.4 |
| Occlusion catheter |
1 |
7 |
0.11 |
0.13 |
2.8 |
3 |
0.20 |
0.25 |
2.4 |
| Coronary stents |
11 |
34 |
0.02 |
0.24 |
1.7 |
2 |
0.07 |
0.85 |
2.6 |
| Neurovascular stents |
2 |
6 |
0.11 |
0.25 |
4.5 |
1 |
0.25 |
0.67 |
5.5 |
| Carotid stents |
1 |
12 |
0.07 |
0.08 |
1.7 |
1 |
0.33 |
0.50 |
5.5 |
| External and internal carotid shunts |
2 |
5 |
0.13 |
0.29 |
5.5 |
2 |
0.20 |
0.50 |
3.7 |
| Peripheral stents |
0 |
7 |
0.13 |
0.00 |
1.0 |
1 |
0.50 |
0.00 |
1.0 |
| Biliary stents |
7 |
13 |
0.05 |
0.35 |
3.1 |
1 |
0.11 |
0.88 |
3.6 |
| Micro vascular clips |
3 |
6 |
0.10 |
0.33 |
5.2 |
2 |
0.17 |
0.60 |
3.7 |
| Stainless steel tunneler vascular graft |
3 |
3 |
0.14 |
0.50 |
10.0 |
1 |
0.20 |
0.75 |
5.1 |
| Cardiopulmonary bypass vascular catheter |
14 |
39 |
0.02 |
0.26 |
1.6 |
5 |
0.05 |
0.74 |
2.0 |
| Coronary stent graft system |
0 |
6 |
0.14 |
0.00 |
1.0 |
1 |
0.50 |
0.00 |
1.0 |
| Catheter tip occluder |
1 |
6 |
0.13 |
0.14 |
3.3 |
2 |
0.25 |
0.33 |
3.3 |
| Synthetic/biological composite vascular graft |
3 |
5 |
0.11 |
0.38 |
6.3 |
2 |
0.17 |
0.60 |
3.7 |
| Valvulotome tools |
3 |
6 |
0.10 |
0.33 |
5.2 |
1 |
0.20 |
0.75 |
5.1 |
| Aortic Valve |
2 |
9 |
0.08 |
0.18 |
2.9 |
0 |
0.33 |
1.00 |
10.0 |
| Mitral Valve |
4 |
7 |
0.08 |
0.36 |
4.8 |
0 |
0.20 |
1.00 |
6.4 |
| Angioplasty Guided Wires |
8 |
11 |
0.05 |
0.42 |
3.7 |
2 |
0.09 |
0.80 |
3.0 |
|
126 |
27 |
||||||||
| Source for A, B, C, G – http://www.medicregister.com | |||||||||
| Source for D,E,F,H,I,J – Computed ratios per formulas below byAviva Lev-Ari, PhD, RN | |||||||||
| D = 1/(1+B+C) = projected market share assuming non-differential production capacity | |||||||||
| E = B/(B+C) = fraction of global among all suppliers | |||||||||
| F = D*E*$F$24+1 = product of “D” and “E”, scaled to be in the range from 1 to 10 | |||||||||
| “H” is the same as “D” but with MA suppliers replacing “US suppliers” | |||||||||
| “I” is the same as “E” but with MA suppliers replacing “US suppliers” | |||||||||
| “J” is the same as “F” but with MA suppliers replacing “US suppliers” | |||||||||
Product Advantage for Partnership with Niche Suppliers in MA
|
Product Concentration Ratio (PRC) for Tools and Devices in use in Cardiology & Vascular Surgery |
Targeting a Niche Supplier based in Massachusetts |
Aiming at the Industry Leader |
| Arterial catheterization kitPRC = 3.6 | Lemaitre Vascular, Inc. www.lemaitre.comBurlington
Weston |
|
| External and internal carotid shuntsPRC = 3.7 | Bard Electrophysiology www.bardep.comLowell
Lemaitre Vascular, Inc. www.lemaitre.com Burlington |
|
| Micro vascular clipsPRC = 3.7 | Lemaitre Vascular, Inc. www.lemaitre.comBurlington
Life Instrument Corporation www.lifeinstruments.com Braintree |
|
| Stainless steel tunneler vascular graftPRC = 5.1 | Lemaitre Vascular, Inc. www.lemaitre.comBurlington | |
| Cardiopulmonary bypass vascular catheterPRC = 2 | Abiomed, Inc. www.abiomed.comDanvers
Vortex Medical Inc www.angiovac.com Norwell Lemaitre Vascular, Inc. www.lemaitre.com Burlington Clinical Instruments Intl., Inc. Southbridge Weston |
|
| Coronary stent graft systemPRC = 2.6 | Lemaitre Vascular, Inc. www.lemaitre.comBurlington | |
| Catheter tip occluderPRC = 2.4 | Lemaitre Vascular, Inc. www.lemaitre.comBurlington
Clinical Instruments Intl., Inc. Southbridge |
|
| Valvulotome toolsPRC = 5.1 | Lemaitre Vascular, Inc. www.lemaitre.comBurlington |
Product Advantage for Partnership with National Leader in MA
| Cardiology & Vascular Surgery Tools and Devices in use | Niche Supplier based in Massachusetts | Industry Leader |
| Neurovascular stentsPRC = 5.5 | Boston Scientific Corporation www.bostonscientific.comNatick | |
| Carotid stents PRC = 5.5 | Boston Scientific Corporation www.bostonscientific.comNatick | |
| Peripheral stentsPRC = 1 | Boston Scientific Corporation www.bostonscientific.comNatick | |
| Biliary stentsPRC = 3.6 | Boston Scientific Corporation www.bostonscientific.comNatick |
Product Advantage for Partnership with Niche Suppliers and National Leader in MA
| Cardiology & Vascular Surgery Tools and Devices in use | Niche Supplier based in Massachusetts | Industry Leader |
| Embolectomy cathetersPRC = 2.4 | Lemaitre Vascular, Inc. www.lemaitre.comBurlington
Clinical Instruments Intl., Inc. Southbridge |
Boston Scientific Corporation www.bostonscientific.comNatick |
| Occlusion catheterPRC = 2.4 | Lemaitre Vascular, Inc. www.lemaitre.comBurlington
Telemed Systems Inc. www.telemedsystems.com Hudson |
Boston Scientific Corporation www.bostonscientific.comNatick |
| Coronary stentsPRC = 2.6 | Lemaitre Vascular, Inc. www.lemaitre.comBurlington | Boston Scientific Corporation www.bostonscientific.comNatick |
| Synthetic/biological composite vascular graftPRC = 3.7 | Lemaitre Vascular, Inc. www.lemaitre.comBurlington | Boston Scientific Corporation www.bostonscientific.comNatick |
| Angioplasty Guided WiresPRC = 3.0 | Arrow International, Walrus DivisionWoburn | Boston Scientific Corporation www.bostonscientific.comNatick |
Source:
http://www.medicregister.com/Cardiology_Vascular_Surgery/Categories/cid2.htm
Penetration Strategy for a Global Supplier Targeting the US Market in Massachusetts
Customized predictions of penetration cost and estimation of potential revenues based on the industry segment concentration ratios in the Table above per Partnership Option are part of an Actionable Strategic Market Entry Plan in Massachusetts.
Contact Us
Aviva Lev-Ari, PhD, RN
Leaders in Pharmaceutical Business Intelligence
Founder & Director of Pharmaceutical Business Intelligence Services
1-617-244-4024
avivalev-ari@alum.berkeley.edu
Follow me on
http://www.linkedin.com/in/avivalevari
https://twitter.com/#!/pharma_BI
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Daniel Menzin
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
komal23ingle
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
Rosalind Codrington, PhD
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
vaishnavee24
zraviv06
zs22
[…] http://pharmaceuticalintelligence.com/2012/06/22/global-supplier-strategy-for-market-penetration-par… […]
[…] http://pharmaceuticalintelligence.com/2012/06/22/global-supplier-strategy-for-market-penetration-par… […]
[…] http://pharmaceuticalintelligence.com/2012/06/22/global-supplier-strategy-for-market-penetration-par… […]
[…] http://pharmaceuticalintelligence.com/2012/06/22/global-supplier-strategy-for-market-penetration-par… […]
[…] http://pharmaceuticalintelligence.com/2012/06/22/global-supplier-strategy-for-market-penetration-par… […]
[…] http://pharmaceuticalintelligence.com/2012/06/22/global-supplier-strategy-for-market-penetration-par… […]
[…] http://pharmaceuticalintelligence.com/2012/06/22/global-supplier-strategy-for-market-penetration-par… […]
[…] http://pharmaceuticalintelligence.com/2012/06/22/global-supplier-strategy-for-market-penetration-par… […]
[…] http://pharmaceuticalintelligence.com/2012/06/22/global-supplier-strategy-for-market-penetration-par… […]
[…] lobal Supplier Strategy for Market Penetration & Partnership Options (Niche Suppliers vs. National Leaders) in the Massachusetts Cardiology & Vascular Surgery Tools and Devices Market for Cardiac Operating Rooms and Angioplasty Suites (A Lev-Ari) http://pharmaceuticalintelligence.com/2012/06/22/global-supplier-strategy-for-market-penetration-par… […]
[…] Abdominal Aortic Aneurysms (AAA): Albert Einstein’s Operation by Dr. Nissen (Aviva Lev-Ari) http://pharmaceuticalintelligence.com/2013/06/11/abdominal-aortic-aneurysms-aaa-albert-einsteins-operation-by-dr-nissen/ The Heart Surgery Specialty: heart transplant, lung transplant, heart-lung transplantation, aortic valve surgery, bypass surgery, minimally invasive cardiac surgery, heart valve surgery, removal of cardiac tumors, reoperation valve surgery (Aviva Lev-Ari) http://pharmaceuticalintelligence.com/?p=14092&preview=true No Early Symptoms – An Aortic Aneurysm Before It Ruptures – Is There A Way To Know If I Have it? (Aviva Lev-Ari) http://pharmaceuticalintelligence.com/2013/06/10/no-early-symptoms-an-aortic-aneurysm-before-it-ruptures-is-there-a-way-to-know-if-i-have-it/ First-of-Its-Kind FDA Approval for ‘AUI’ Device with Endurant II AAA Stent Graft: Medtronic Expands in Endovascular Aortic Repair in the United States (Aviva Lev-Ari) http://pharmaceuticalintelligence.com/2013/05/30/first-of-its-kind-fda-approval-for-aui-device-with-endurant-ii-aaa-stent-graft-medtronic-expands-in-endovascular-aortic-repair-in-the-united-states/ Abdominal Aortic Aneurysm: Endovascular repair and open repair resulted in similar long-term survival (Aviva Lev-Ari) http://pharmaceuticalintelligence.com/2012/12/03/abdominal-aortic-aneurysm-endovascular-repair-and-open-repair-resulted-in-similar-long-term-survival/ EUROPCR 2013, Paris 5/21-5/24, 2013 Conference for Cardiolovascular Intervention and Interventional Medicine (Aviva Lev-Ari) http://pharmaceuticalintelligence.com/2013/05/29/europcr-2013-paris-521-524-2013-conference-for-cardiolovascular-intervention-and-interventional-medicine/ Genomics & Genetics of Cardiovascular Disease Diagnoses: A Literature Survey of AHA’s Circulation Cardiovascular Genetics, 3/2010 – 3/2013 (Aviva Lev-Ari) http://pharmaceuticalintelligence.com/2013/03/07/genomics-genetics-of-cardiovascular-disease-diagnoses-a-literature-survey-of-ahas-circulation-cardiovascular-genetics-32010-32013/ Competition in the Ecosystem of Medical Devices in Cardiac and Vascular Repair: Heart Valves, Stents, Catheterization Tools and Kits for Open Heart and Minimally Invasive Surgery (MIS) (Aviva Lev-Ari) http://pharmaceuticalintelligence.com/2012/06/22/competition-in-the-ecosystem-of-medical-devices-in-cardiac-and-vascular-repair-heart-valves-stents-catheterization-tools-and-kits-for-open-heart-and-minimally-invasive-surgery-mis/ Bioabsorbable Drug Coating Scaffolds, Stents and Dual Antiplatelet Therapy (Aviva Lev-Ari) http://pharmaceuticalintelligence.com/2013/05/29/bioabsorbable-drug-coating-scaffolds-stents-and-dual-antiplatelet-therapy/ Vascular Repair: Stents and Biologically Active Implants (larryhbern) http://pharmaceuticalintelligence.com/2013/05/04/stents-biologically-active-implants-and-vascular-repair/ Drug Eluting Stents: On MIT’s Edelman Lab’s Contributions to Vascular Biology and its Pioneering Research on DES (larryhbern) http://pharmaceuticalintelligence.com/2013/04/25/contributions-to-vascular-biology/ Coronary Artery Disease – Medical Devices Solutions: From First-In-Man Stent Implantation, via Medical Ethical Dilemmas to Drug Eluting Stents (Aviva Lev-Ari) http://pharmaceuticalintelligence.com/2012/08/13/coronary-artery-disease-medical-devices-solutions-from-first-in-man-stent-implantation-via-medical-ethical-dilemmas-to-drug-eluting-stents/ Survivals Comparison of Coronary Artery Bypass Graft (CABG) and Percutaneous Coronary Intervention (PCI) / Coronary Angioplasty (larryhbern) http://pharmaceuticalintelligence.com/2013/06/23/comparison-of-cardiothoracic-bypass-and-percutaneous-interventional-catheterization-survivals/ Trans-apical Transcatheter Aortic Valve Replacement in a Patient with Severe and Complex Left Main Coronary Artery Disease (LMCAD) (larryhbern) http://pharmaceuticalintelligence.com/2013/06/17/management-of-difficult-trans-apical-transcatheter-aortic-valve-replacement-in-a-patient-with-severe-and-complex-arterial-disease/ Transcatheter Aortic Valve Replacement (TAVR): Postdilatation to Reduce Paravalvular Regurgitation During TAVR with a Balloon-expandable Valve (larryhbern) http://pharmaceuticalintelligence.com/2013/06/17/postdilatation-to-reduce-paravalvular-regurgitation-during-transcatheter-aortic-valve-replacement/ Svelte Medical Systems’ Drug-Eluting Stent: 0% Clinically-Driven Events Through 12-Months in First-In-Man Study (Aviva Lev-Ari) http://pharmaceuticalintelligence.com/2013/05/28/svelte-medical-systems-drug-eluting-stent-0-clinically-driven-events-through-12-months-in-first-in-man-study/ Acute and Chronic Myocardial Infarction: Quantification of Myocardial Perfusion Viability – FDG-PET/MRI vs. MRI or PET alone (Justin Pearlman, Aviva Lev-Ari) http://pharmaceuticalintelligence.com/2013/05/22/acute-and-chronic-myocardial-infarction-quantification-of-myocardial-viability-fdg-petmri-vs-mri-or-pet-alone/ Biomaterials Technology: Models of Tissue Engineering for Reperfusion and Implantable Devices for Revascularization (larryhbern) http://pharmaceuticalintelligence.com/2013/05/05/bioengineering-of-vascular-and-tissue-models/ Revascularization: PCI, Prior History of PCI vs CABG (A Lev-Ari) http://pharmaceuticalintelligence.com/2013/04/25/revascularization-pci-prior-history-of-pci-vs-cabg/ Accurate Identification and Treatment of Emergent Cardiac Events (larryhbern) http://pharmaceuticalintelligence.com/2013/03/15/accurate-identification-and-treatment-of-emergent-cardiac-events/ FDA Pending 510(k) for The Latest Cardiovascular Imaging Technology (A Lev-Ari) http://pharmaceuticalintelligence.com/2013/01/28/fda-pending-510k-for-the-latest-cardiovascular-imaging-technology/ The ACUITY-PCI score: Will it Replace Four Established Risk Scores — TIMI, GRACE, SYNTAX, and Clinical SYNTAX (A Lev-Ari) http://pharmaceuticalintelligence.com/2013/01/03/the-acuity-pci-score-will-it-replace-four-established-risk-scores-timi-grace-syntax-and-clinical-syntax/ Nitric Oxide and it’s impact on Cardiothoracic Surgery (tildabarliya) http://pharmaceuticalintelligence.com/2012/12/15/nitric-oxide-and-its-impact-on-cardiothoracic-surgery/ CABG or PCI: Patients with Diabetes – CABG Rein Supreme (A Lev-Ari) http://pharmaceuticalintelligence.com/2012/11/05/cabg-or-pci-patients-with-diabetes-cabg-rein-supreme/ To Stent or Not? A Critical Decision (A Lev-Ari) http://pharmaceuticalintelligence.com/2012/10/23/to-stent-or-not-a-critical-decision/ Endothelin Receptors in Cardiovascular Diseases: The Role of eNOS Stimulation (A Lev-Ari) http://pharmaceuticalintelligence.com/2012/10/04/endothelin-receptors-in-cardiovascular-diseases-the-role-of-enos-stimulation/ Absorb™ Bioresorbable Vascular Scaffold: An International Launch by Abbott Laboratories (Aviva Lev-Ari) http://pharmaceuticalintelligence.com/2012/09/29/absorb-bioresorbable-vascular-scaffold-an-international-launch-by-abbott-laboratories/ Carotid Stenting: Vascular surgeons have pointed to more minor strokes in the stenting group and cardiologists to more myocardial infarctions in the CEA cohort. (A Lev-Ari) http://pharmaceuticalintelligence.com/2012/09/21/carotid-stenting-vascular-surgeons-have-pointed-to-more-minor-strokes-in-the-stenting-group-and-cardiologists-to-more-myocardial-infarctions-in-the-cea-cohort/ New Drug-Eluting Stent Works Well in STEMI (A Lev-Ari) http://pharmaceuticalintelligence.com/2012/08/22/new-drug-eluting-stent-works-well-in-stemi/ lobal Supplier Strategy for Market Penetration & Partnership Options (Niche Suppliers vs. National Leaders) in the Massachusetts Cardiology & Vascular Surgery Tools and Devices Market for Cardiac Operating Rooms and Angioplasty Suites (A Lev-Ari) http://pharmaceuticalintelligence.com/2012/06/22/global-supplier-strategy-for-market-penetration-par… […]
[…] http://pharmaceuticalintelligence.com/2012/06/22/global-supplier-strategy-for-market-penetration-par… […]
[…] http://pharmaceuticalintelligence.com/2012/06/22/global-supplier-strategy-for-market-penetration-par… […]
[…] http://pharmaceuticalintelligence.com/2012/06/22/global-supplier-strategy-for-market-penetration-par… […]